UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) GeneSight, effective January 1, 2025, in a number of plans, which Raymond James tells investors in a research note is a major blow given the size of UnitedHealth, which covers a mid-teens portion of the commercial market and raises additional questions on the ability of GeneSight to drive growth more broadly. The firm thinks the market is overshooting and would be buyers, thinks the Myriad business ex-GeneSight is a mid- to high-single digit grower and that GeneSight can remain additive over the longer term, even if it faces disruption in 2025. The firm made no change to its Outperform rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MYGN:
- Piper says Myriad appears to be trading down on GeneSight coverage change
- Myriad weakness due to UnitedHealth coverage update, says Stephens
- MYGN Upcoming Earnings Report: What to Expect?
- Myriad Genetics announces strategic partnership with jscreen
- Myriad Genetics, Flatiron partner to make genetic testing more accessible
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
